ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Raynaud’s phenomenon"

  • Abstract Number: 0499 • ACR Convergence 2021

    Preliminary Assessment of Internal Reliability and Construct Validity of Long and Short-form Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaires

    John Pauling1, Lan Yu2, Christopher Denton3, Tracy Frech4, Ariane Herrick5, Laura Hummers6, Lesley Ann Saketkoo7, Ami Shah8, Dinesh Khanna9 and Robyn Domsic2, 1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2University of Pittsburgh, Pittsburgh, PA, 3University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 4University of Utah, Salt Lake City, UT, 5University of Manchester, Salford, United Kingdom, 6Johns Hopkins Univerisity, Baltimore, MD, 7University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, 8Johns Hopkins Rheumatology, Baltimore, MD, 9University of Michigan, Ann Arbor, MI

    Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome instrument devised to assess the severity and impact of SSc-RP.…
  • Abstract Number: 1365 • ACR Convergence 2021

    Release of High-Mobility Group Box-1 After an Raynaud’s Attack Potentially Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production in Systemic Sclerosis

    Isabella Atzeni1, Yehya Al-Adwi2, Berber Doornbos-van der Meer2, Amel Eman Abdulle2, Anniek Van Roon2, Alja J. Stel2, Harry Van Goor2, Andries Smit2, Johanna Westra2 and Douwe J Mulder2, 1University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, 2University of Groningen, University Medical Centre Groningen, Groningen, Netherlands

    Background/Purpose: Raynaud’s Phenomenon (RP) leading to repetitive ischaemia and reperfusion (IR) stress, is the first recognisable sign of systemic sclerosis (SSc). Although RP has been…
  • Abstract Number: 1376 • ACR Convergence 2021

    Outcome Reporting in Systemic Sclerosis-Related Digital Ulcers: A Scoping Review

    Michael Hughes1, Nancy Maltez2, Edith Brown3, Virginia Hickey4, Heiyoung Park5, Beverley Shea2, John Pauling6, Susanna Proudman7, Peter Merkel8 and Ariane Herrick9, 1Tameside and Glossop Integrated NHS Foundation Trust, Manchester, United Kingdom, 2University of Ottawa, Ottawa, ON, Canada, 3n/a, Manchester, United Kingdom, 4n/a, Adelaide, Australia, 55. National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, 6Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 7University of Adelaide, Medindie, Australia, 8University of Pennsylvania, Philadelphia, PA, 9University of Manchester, Salford, United Kingdom

    Background/Purpose: Digital ulcers (DUs) are a major cause of pain and disability in patients with systemic sclerosis (SSc). Despite the availability of a range of…
  • Abstract Number: 1387 • ACR Convergence 2021

    Macrovascular Dysfunction and Its Clinical Implication in Systemic Sclerosis

    Devender Bairwa1, Chengappa Kavadichanda2, sanket Shah3, Anoop Mathew1, saikumar dunga3, Aishwarya Gopal3, Molly Mary Thabah1 and VirSingh Negi1, 1Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India, 2JIPMER, Pondicherry, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

    Background/Purpose: Microvascular dysfunction is a key and determining feature of scleroderma (SSc). But contrary to earlier belief there is emerging evidence to suggest co-occurrence of…
  • Abstract Number: 1635 • ACR Convergence 2021

    Nailfold Capillary Microscopy in Children with Raynaud’s Phenomenon. Potential Predictive Value of Capillary Loss for Future Connective Tissue Disease?

    Claudette Farenhorst1, Anniek Van Roon1, Anne van Gessel1, Alja Stel1, Hendrika Bootsma2, Wineke Armbrust1 and Douwe J Mulder1, 1University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Nailfold capillary microscopy (NCM) is a cornerstone in the diagnosis of Systemic Sclerosis (SSc) in adulthood. Although Raynaud’s phenomenon (RP) is common in childhood,…
  • Abstract Number: 0180 • ACR Convergence 2021

    Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Computed Tomography in Patients with Systemic Sclerosis

    Attila Feher1, Nabil Boutagy1, Evangelos Oikonomou1, Stephanie Thorn1, Yi-Hwa Liu1, Edward Miller1, Albert Sinusas1 and Monique Hinchcliff2, 1Yale School of Medicine, New Haven, CT, 2Yale School of Medicine, Westport, CT

    Background/Purpose: To investigate the association between Raynaud phenomenon (RP) and coronary microvascular dysfunction, we measured myocardial flow reserve (MFR) using positron emission tomography/computed tomography (PET/CT)…
  • Abstract Number: 0391 • ACR Convergence 2021

    High Frequency Ultrasound Imaging of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis: An Objective Outcome Measure to Track Change over Time

    Elizabeth Marjanovic1, Calvin Heal1, Tonia Moore1, Joanne Manning2, Sarah Wilkinson1, Graham Dinsdale2, Mark Dickinson1, Jack Wilkinson1, Ariane Herrick3 and Andrea Murray1, 1University of Manchester, Manchester, United Kingdom, 2Salford Royal NHS Foundation Trust, Manchester, United Kingdom, 3University of Manchester, Salford, United Kingdom

    Background/Purpose: There are currently no validated objective measures of systemic sclerosis (SSc)-related skin thickening and this hampers clinical trials of potential new treatments. The modified…
  • Abstract Number: 0394 • ACR Convergence 2021

    Hyperspectral Imaging in Systemic Sclerosis-Raynaud Phenomenon

    Akash Gupta1, Shannon Teaw2, Alyssa Williams2, F. Perry Wilson3, Brandon Sumpio4, Bauer Sumpio4 and Monique Hinchcliff5, 1Department of Medicine, Yale University School of Medicine, New Haven, CT, 2Section of Rheumatology, Allergy & Immunology, Department of Medicine, Yale School of Medicine, New Haven, CT, 3Section of Nephrology, Department of Medicine, Yale School of Medicine, New Haven, CT; Department of Medicine Clinical and Translational Research Accelerator Yale School of Medicine, New Haven, CT, 4Division of Vascular Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT, 5Yale School of Medicine, Westport, CT

    Background/Purpose: Raynaud phenomenon (RP), a microcirculatory, vasospastic disorder, may be primary or secondary to an autoimmune disease [e.g., an early indicator of systemic sclerosis (SSc)].…
  • Abstract Number: 0395 • ACR Convergence 2021

    RNA Polymerase III Autoantibody Levels and Risk of Systemic Sclerosis in Patients with Raynaud Phenomenon

    Megan Lockwood1, Yuqing Zhang2, Marcy Bolster1, Sara Schoenfeld1, Xiaoqing Fu1, Seth Brownmiller1, Ana Fernandes1 and Flavia Castelino1, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Quincy, MA

    Background/Purpose: Raynaud phenomenon is often the initial manifestation in systemic sclerosis (SSc) and can precede other SSc symptoms by years (1). Several SSc-specific autoantibodies are…
  • Abstract Number: 0399 • ACR Convergence 2021

    Nailfold Videocapillaroscopy Findings and Associations with Organ Involvement in Mixed Connective Tissue Disease

    Camille Kasser, Gonçalo Boleto, Yannick Allanore and Jerome Avouac, Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France

    Background/Purpose: Mixed connective tissue disease (MCTD) is a rare autoimmune condition characterized by Raynaud’s phenomenon, positivity of antibodies targeting the U1 small nuclear ribonucleoprotein particle…
  • Abstract Number: 1392 • ACR Convergence 2020

    Long-Term Tolerability of Aminaphtone in Raynaud’s Phenomenon Secondary to Systemic Sclerosis

    Alberto Sulli1, Sabrina Paolino1, Giorgia Ferrari1, Carmen Pizzorni1, Elvis Hysa1, Maurizio Cutolo1 and Emanuele Gotelli1, 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genoa, Italy

    Background/Purpose: Aminaphtone has been used for many years to treat microvascular disorders. In vitro Aminaphtone counteracts vasoconstriction downregulating endothelin-1 production and interferes with adhesion molecules…
  • Abstract Number: 1396 • ACR Convergence 2020

    Digital Artery Volume Index (Davix©) Predicts Onset of Future Digital Ulcers in Patients with Systemic Sclerosis

    Klodian Gjeloshi1, Giovanni Lettieri2, Fiammetta Danzo1, Giuseppina Abignano3, Mark Hinton4, Anne-Maree Dean5, Giovanna Cuomo6, Olga Kubassova7 and Francesco Del Galdo5, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK and Internal Medicine Department, University of Campania Luigi Vanvitelli, Naples, Italy, Leeds, United Kingdom, 2Radiology Department, San Carlo Hospital, Potenza, Italy, Potenza, Italy, 3Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, England, United Kingdom, 4IAG CEO, London, United Kingdom, London, United Kingdom, 5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, 6Internal Medicine Department, University of Campania Luigi Vanvitelli, Naples, Italy, Naples, Italy, 7Image Analysis Group, London, United Kingdom

    Background/Purpose: Neointima proliferation is a key pathologic feature of Systemic Sclerosis (SSc), causing arterial vessel narrowing. It is a recognised culprit pathological lesion in Digital…
  • Abstract Number: 149 • 2019 ACR/ARP Annual Meeting

    Teaching Rare Diseases Through Role Play: Results of an Experimental Workshop About Raynaud Phenomenon

    Sébastien Sanges1, Sandrine Morell-Dubois 2, Meryem-Maud Farhat 3, Morgane Assaraf 3, Marc LAMBERT 4, Vincent Sobanski 3, David Launay 3 and Eric Hachulla 5, 1CHRU Lille, Lille, France, 2Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, 3CHU Lille, Lille, France, 4Lille University Hospital, Lille, France, 5Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France

    Background/Purpose: Systemic autoimmune diseases are mostly taught through theoretical lectures, which do not allow for the acquisition of physical examination skills and semiologic confrontation. We…
  • Abstract Number: 868 • 2019 ACR/ARP Annual Meeting

    The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the “Tamer”‘ Study

    Robyn Domsic1, Maureen Laffoon 1, Balasubramani Goundappa 2, Thomas Medsger 1, Robert Lafyatis 1 and Steven Wisniewski 1, 1University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh Epidemiology Data Center, Pittsburgh, PA

    Background/Purpose: Statins have pleiotropic effects felt to influence in their beneficial cardiovascular effects.  These include increased nitric oxide production and improved endothelial function, modulation of…
  • Abstract Number: 1635 • 2019 ACR/ARP Annual Meeting

    Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis

    Barbara Ruaro1, Elisa Alessandri 2, Massimo Ghio 3, Carmen Pizzorni 4, Sabrina Paolino 4, Andrea Casabella 5, Antonio De Tanti 6, Alberto Sulli 7 and Maurizio Cutolo 8, 11 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy, 21. Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, 3Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, 4Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, 51 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, 62 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Fontanellato, Italy, 7Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, 8Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy

    Background/Purpose: To evaluate any correlation between the Raynaud's Condition Score (RCS) and the morphological and functional methods available to evaluate microvascular damage in systemic sclerosis (SSc) patients (1-4). Methods: Sixty-six…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology